SANTA ANA, CA--(NewMediaWire - Dec 28, 2015) - ADVANTIS
CORPORATION (OTC
PINK: ADVT) has announced the finalization and execution
of participating Southern California 7-Eleven and 76 Gas Station
distribution deal.
On the dawn of signing its first exclusive distribution
agreement with LipMedRX, LLC., Advantis Corp announced it has
successfully negotiated, drafted, and executed an agreement with
participating Southern California 7-Eleven and 76 Gas Station
stores.
Advantis Corp's Vice President, Geoffrey Broderick, stated in a
recent press conference, "First we have under our corporate belt
what is the first ground breaking cold and flu preventive product
in the lip balm industry; then we achieved the execution of a deal
to have Advantis be the exclusive distributor, and now we have
taken the ultimate step of successfully lining up 7-Eleven and 76
Gas Stations to officially launch LipMedRX in participating
Southern California 7-Eleven and 76 Gas Station locations."
Advantis Director Woo Kim reiterated, "This great news reflects
one of the many steps Advantis has been taking to help build
shareholder value by timing the recent Advantis rebranding process
to coincide with the imminent finalization of several agreements
which will no doubt welcome Advantis to the big leagues." Broderick
added, "This focus on shareholder value is starting to become
apparent as we finally move from mere negotiation and contract to a
'brick and mortar' presence with a product that promises to bring
great success in 2016 and beyond!"
LipMedRX is an innovative anti-germ lip balm protectant, for
which studies have shown to be highly effective in killing those
germs associated with cold and flu on the lips before they enter
the mouth. According to a report released by LipMedRX, LLC, the
Anti-Flu & Cold Lip Balm Protectant is the first ever lip balm
that kills germs on the lips before they can enter the body. The
product was designed to not only provide protection from germs but
also be a moisturizing agent that keeps lips soft and smooth.
According to Geoffrey Broderick, "This is the type of innovation
that has the ability to sweep the market share of its product
category, and the good news is that this is just one of several
deals that we are working on... stay tuned; the best has yet to
come."
ABOUT Advantis Corporation
Advantis Corporation (ADVT)
focuses on the development of innovative products that supply the
medical, research, and pharmaceutical industries. In addition, the
company is establishing domestic and international partnerships
with businesses that develop and sell proprietary consumer products
and services. Product lines for consumer health care, music and
entertainment sectors are in development.
Forward Looking Statements: This news release contains
forward-looking statements made by ADVANTIS CORPORATION. All such
statements included in this press release, other than statements of
historical fact, are forward-looking statements. Although
management believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance
that such expectations will prove to have been correct. Actual
results may differ materially from those indicated by these
statements. The following risk factors, among others, could cause
actual results to differ materially from those described in any
forward-looking statements. These risks and uncertainties include,
but are not limited to, economic conditions, changes in the law or
regulations, demand for products of the Company, the effects of
competition and other factors that could cause actual results to
differ materially from those projected or represented in the
forward looking statements. Forward-looking statements are
typically identified by the words: believe, expect, anticipate,
intend, estimate, and similar expressions or which by their nature
refer to future events. The Company is not entitled to rely on the
safe harbor provisions of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934 because it
is not registered under either Act.